ASPREE
Aspirin in Reducing Events in the Elderly
ASPREE

STUDY FEATURES

• Focused entirely on people aged over 70 years.
• Looking at an outcome that matters – to prolong a high quality of disability-free life
• International study funded by the peak medical research organisations in Australia (NHMRC, CSIRO) and the USA (NIH).
• Collaboration between Universities, GPs, Government and the community
• Largest primary prevention trial ever undertaken in Australia
Why the emphasis on the over 70’s?

- People over 70 are under-represented in clinical studies.
- Results from trials in other age groups are extrapolated to older people;
  - Yet older people receive most medical treatments.
- Lifespan and demographic changes in western world ➔ ageing population
STUDY BASICS

• Daily low-dose aspirin (100mg enteric-coated) or placebo
• 19,000 participants (12,500 AUS; 6,500 USA)
• Aged 70 plus, able-bodied
• Follow-up 5 years
To be involved in the study, speak with me after or call 1800 728 745.

Website: www.aspree.org